Role of pharmacogenomics in drug discovery and development

Indian Journal of Pharmacology

Volumn 40, Issue 4, 2008, Pages 137-143

  Surendiran, A ^a   Pradhan, S ^a   Adithan, C ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Drug; Genotype; Pharmaceuticals; Pharmacogenetics; Pharmacogenomics

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRINOTECAN; LISINOPRIL; UNCLASSIFIED DRUG; WARFARIN;

CLINICAL TRIAL; COST; DRUG DESIGN; DRUG EFFICACY; DRUG LABELING; DRUG SAFETY; ETHNIC DIFFERENCE; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; PHARMACOGENOMICS; PRACTICE GUIDELINE; PREDICTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 53849110630     PISSN: 02537613     EISSN: 19983751     Source Type: Journal    
DOI: 10.4103/0253-7613.43158     Document Type: Review

References (46)

1. McCarthy AD, Kennedy JL, Middleton LT. Pharmacogenetics in drug development. Philos Trans R Soc Lond B Biol Sci 2005;360:1579-88.
2. Lee SY, Nam MH, Kim JS, Kim JW. A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement. J Korean Med Sci 2007;22:557-9.
3. Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 2006;62:35-46.
4. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42.
5. Tsai CT, Fallin D, Chiang FT, Hwang JJ, Lai LP, Hsu KL, et al. Angiotensinogen gene haplotype and hypertension: interaction with ACE gene I allele. Hypertension 2003;41:9-15.
6. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Genetic polymorphisms of the beta 2-adrenergic receptor in nocturnal and nonnocturnal asthma: Evidence that Gly16 correlates with the nocturnal phenotype. J Clin Invest 1995;95:1635-41.
7. Durham LK, Webb SM, Milos PM, Clary CM, Seymour AB. The serotonin transporter polymorphism, 5HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacology (Berl) 2004;174:525-9.
8. Kronenberg S, Apter A, Brent D, Schirman S, Melhem N, Pick N, et al. Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness and Side Effects in Children with Depression and/or Anxiety Disorders. J Child Adolesc Psychopharmacol 2007;17:741-50.
9. Dorado P, Peñas-Lledó EM, González AP, Cáceres MC, Cobaleda J, Llerena A. Increased risk for major depression associated with the short allele of the serotonin transporter promoter region (5-HTTLPR-S) and the CYP2C9*3 allele. Fundam Clin Pharmacol 2007;21:451-3.
10. Dubey AK, Subish PP, Ravi SP, Prabhu M, Bista D, Khadka CA. Understanding the essentials of pharmacogenomics- the potential implications for the future pharmacotherapy. J Clin Diagn Res 2008;2:681-9.
11. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997;100:3184-8.
12. Tsuchihashi Z, Dracopoli NC. Progress in high throughput SNP genotyping methods. Pharmacogenomics J 2002;2:103-10.
13. Dickson M, Gagnon JP. The cost of new drug discovery and development. Discov Med 2004;4:172-9.
14. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85.
15. Burgess J, Golden J. Cracking the druggable genome. Bio-IT World [online] 2002 [cited 2008 March 7] Available from: http://www.bio-itworld.com/archive/ 100902/firstbase.html.
16. Hopkins AL, Groom CR. The druggable genome. Nat Rev Drug Discov 2002;1:727-30.
17. Imming P, Sinning C, Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov 2006;5:821-34.
18. Cavallari U, Trabetti E, Malerba G, Biscuola M, Girella D, Olivieri O, et al. Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery disease. BMC Med Genet 2007;8:59.
19. Birkett DJ, Mackenzie PI, Veronese ME, Miners LO. In vitro approaches can predict human drug metabolism. Trends Pharmacol Sci 1993;14:292-4.
20. Abraham BK, Adithan C. Genetic polymorphism of CYP2D6. Indian J Pharmacol 2001;33:147-69.
21. Monica RP, Snehal G. Pharmacogenomics and modern therapy. Indian J Pharm Sci 2007;69:167-72.
22. Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer: Herceptin Multinational Investigator Study Group. Semin Oncol 1999;26:71-7.
23. de Maat MP, Jukema JW, Ye S, Zwinderman AH, Moghaddam PH, Beekman M, et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999;83:852-6.
24. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen C, Hansen PS et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: A substudy of the Scandinavian simvastatin survival study. Circulation 2000;101:1366-71.
25. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijff P, McPherson R, Bruschke AVG, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis: The Regression Growth Evaluation Statin Study Group. N Engl J Med 1998;338:86-93.
26. Ordovas JM, Lopez-Miranda J, Perez-Jimenez F, Rodriguez C, Park JS, Cole T, et al. Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy. Atherosclerosis 1995;113:157-66.
27. Preventiongenetics. Research genotyping. [webpage in internet] 2008, Feb 29. Available from: http://www.preventiongenetics.com/resgeno/ listofprices.htm. [cited on 2008 Mar 6].
28. Mani S. UGT1A1 polymorphism predicts irinotecan toxicity: Evolving proof. AAPS PharmSci 2001;3:2.
29. Huang SM, Goodsaid F, Rahman A, Frueh F, Lesko LJ. Application of pharmacogenomics in clinical pharmacology. Toxicol Mechanisms Met 2006;16:89-99.
30. Lee SY, Kim JS, Kim JW. A case of intolerance to warfarin dosing in an intermediate metabolizer of CYP2C9. Yonsei Med J 2005;46:843-6.
31. Shi MM, Bleavins MR, de la Iglesia F. Pharmacogenetic application in drug development and clinical trials. Drug Metab Dispos 2001;29:591-5.
32. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: Regulatory, scientific, and clinical issues. J Thromb Thrombolysis 2008;25:45-51.
33. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-7.
34. Relling MV, Giacomini KM. Pharmacogenetics. In: Laurence LB, John SL, Keith LP, editors. Goodman & Gilmans' The pharmacological basis of therapeutics. 11th ed. New Delhi: McGrawHill 2005; p. 93-115.
35. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000;97:10483-8.
36. Kohno M, Yokokawa K, Minami M, Kano H, Yasunari K, Hanehira T, et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999;106:544-9.
37. Cannella G, Paoletti E, Barocci S, Massarino F, Delfino R, Ravera G, et al. Angiotensin-converting enzyme gene polymorphism and reversibility of uremic left ventricular hypertrophy following long-term antihypertensive therapy. Kidney Int 1998;54:618-26.
38. Hernandez D, Lacalzada J, Salido E, Linares J, Barragan A, Lorenzo V, et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 2000;58:889-97.
39. Kwon JM, Goate AM. The candidate gene approach. Alcohol Res Health 2000;24:164-8.
40. Roses AD. Pharmacogenetics and the practice of medicine. Nature 2000;405:857-65.
41. Johnson JA. Drug target pharmacogenomics: An overview. Am J Pharmacogenomics 2001;1:271-81.
42. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: Clinical perspectives on the utility of genotyping. Pharmacogenomics 2006;7:1211-21.
43. Guidance for industry. Pharmacogenomic data submission [pdf document in internet] 2005. Available from http://www.fda.gov/Cber/gdlns/pharmdtasub.htm. [cited on 2008 Feb 29].
44. Rosemary J, Adithan C. The Pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol 2007;2:93-109.
45. Little S. The impact of FDA guidance on pharmacogenomic data submissions on drug development. I Drugs 2005;8:648-50.
46. Bullock PL. Pharmacogenetics and its impact on drug development. Drug Benefit Trends 1999;11:53-4.